PTGX
Protagonist·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PTGX
Protagonist Therapeutics, Inc.
A biopharmaceutical company that developing peptide-based new chemical entities for the treatment of inflammatory bowel disease
Pharmaceutical
08/22/2006
08/11/2016
NASDAQ Stock Exchange
126
12-31
Common stock
7700 Gateway Boulevard, Suite 140, Newark, California 94560-1160
--
Protagonist Therapeutics, Inc., incorporated in Delaware on August 22, 2006, is headquartered in Milpitas, California. The company is a biopharmaceutical company, and its new peptide-based chemical entities rusfertide and JNJ-2113 (formerly PN-235) are in different stages of development, both derived from proprietary discovery technology platforms. The company's clinical programs are divided into two categories of diseases: (i) hematological and hematological diseases, and (ii) inflammatory and immunomodulatory diseases.
Company Financials
EPS
PTGX has released its 2025 Q3 earnings. EPS was reported at -0.62, versus the expected -0.64, beating expectations. The chart below visualizes how PTGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PTGX has released its 2025 Q3 earnings report, with revenue of 4.71M, reflecting a YoY change of 0.79%, and net profit of -39.34M, showing a YoY change of -18.46%. The Sankey diagram below clearly presents PTGX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
